Silver Grove Financial Group’s Castle Biosciences CSTL Stock Holding History

Silver Grove Financial Group’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.72K	Buy	+156	New	+$3.48K	﹤0.01%	1336

Other funds holding CSTL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Allianz Asset Management Munich, Germany $112B AUM 36.28% 1-Year Est. Return

SPPAM

Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Silver Grove Financial Group's CSTL Position: Q2 2026 in Review

Silver Grove Financial Group opened a new position in Castle Biosciences (CSTL) in Q2 2026: 156 shares worth $3.72K. The stake represents ﹤0.01% of the portfolio and ranks #1336 among its holdings.

176 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

Silver Grove Financial Group held 156 shares of Castle Biosciences worth $3.72K as of Q2 2026.
Castle Biosciences was a new Silver Grove Financial Group position in Q2 2026.
Castle Biosciences made up ﹤0.01% of Silver Grove Financial Group's portfolio in Q2 2026, its #1336 holding.
176 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Silver Grove Financial Group's 13F filing for Q2 2026, filed 13 Aug 2026.